| How It Works | Production Process | Milestones

A platform of promise.

The DiversitAb™ Platform is the first-of-its-kind technology for producing fully human antibodies for the prevention and treatment of disease. The technology is the first and only method to produce fully human antibodies without using human serum to provide therapeutic treatments for a variety of conditions including cancers, infectious diseases such as influenza, Ebola and MERS-CoV, as well as autoimmune disorders and inflammation.


Enhancing nature’s healing.
The platform originated in a lab at the University of Massachusetts, Amherst with an innovative approach to leveraging large animals genetically designed to make fully human polyclonal antibodies. Just as nature has designed our bodies to produce antibodies to emulate disease; the DiversitAb™ Platform models nature to emulate our antibody defenses by producing polyclonal antibodies in cows that enhance the body’s natural process for fighting disease and provide immediate protection or passive immunity. The platform also produces the entire repertoire of human antibodies (similar to human response).